J&J Sells Rolaids To Sanofi, But What Goes Next?
For the past two weeks, there was rising speculation that Johnson & Johnson may have unloaded a sizable chunk of its troubled consumer health business to Sanofi, which owns Chattem, another player in the over-the-counter business. Why? The US Federal Trade Commission web site noted that a deal had been approved, but details were not mentioned.
As it turns out, the deal involved the worldwide rights to the Rolaids antacid brand and nothing more. J&J (JNJ) was silent, but Chattem issued an upbeat announcement. The acquisition “represents a rare opportunity to obtain an iconic brand,” says Chattem ceo Za...
Source: Pharmalot - January 7, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Chattem Consent Decree FDA JJ Johnson & Johnson Rolaids Sanofi Source Type: blogs
